Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01967810 · ClinicalTrials.gov registry record · Phase 2
ANG1005 in Patients With Recurrent High-Grade Glioma
A Phase 2 study, sponsored by Angiochem.
- Completed
- Registry status
- Phase 2
- Development phase
- 73
- Enrollment target
NCT01967810 is a Phase 2 study that has completed, run by Angiochem. The registered enrollment target is 73 participants.
The verdict
NCT01967810, a Phase 2 study, has completed, sponsored by Angiochem.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 73 participants
- Enrollment target
Study Summary
This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.
Interventions
- DRUG Bevacizumab
- DRUG ANG1005
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2013-10 |
| Est. Completion | 2017-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01967810
The ClinicalTrials.gov registry entry for NCT01967810 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Angiochem, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Bevacizumab is the first listed.
NCT01967810 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01967810 about?
NCT01967810 is a clinical study titled "ANG1005 in Patients With Recurrent High-Grade Glioma". This is a Phase 2 study to see if an investigational drug, ANG1005, can shrink tumor cells in patients with high-grade glioma. Another purpose of this study is to assess the efficacy, safety, tolerability, and pharmacokinetics (PK) of ANG1005 in patients.
What is the current status of trial NCT01967810?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 73 participants. The study started on 2013-10. Estimated completion is 2017-09.
What interventions are being tested in trial NCT01967810?
The interventions under investigation include: Bevacizumab (DRUG), ANG1005 (DRUG).
Who is sponsoring clinical trial NCT01967810?
This trial is sponsored by Angiochem, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.